探索脆弱状态和血液生物标志物:对阿尔茨海默氏症诊断的多维方法
Aurora Cermelli1, Armando Crisafi2, Alberto Mario Chiarandon1
1Aging Brain and Memory Clinic, Department of Neuroscience "Rita Levi Montalcini", University of Torino, 10126 Turin, Italy.
Geriatrics (Basel, Switzerland)
|October 28, 2025
概括
通过多维预后指数 (MPI) 测量的脆弱性与阿尔茨海默病 (AD) 的血p-tau181水平较高有关. 将MPI与血液生物标志物的结合提高了AD诊断.
科学领域:
- 老年医学 老年医学
- 神经学 神经学
- 生物标志物研究 生物标志物研究
背景情况:
- 虚弱,一种降低生理储备的综合征,在患有认知障碍的老年人中越来越重要.
- 阿尔茨海默病 (AD) 诊断依赖于临床评估,认知测试和侵入性生物标志物.
- 与AD生物标志物一起探索虚弱的作用可以改进诊断方法.
研究的目的:
- 调查脆弱性 (多维预后指数 - MPI) 和阿尔茨海默病 (AD) 之间的关联.
- 检查MPI,认知表现和AD的血生物标志物之间的相关性.
- 评估血和脑脊液 (CSF) AD生物标志物之间的关系.
主要方法:
- 40名患有认知衰退的患者的横截面研究,根据CSFAT[N]概况分为AD (n=20) 和非AD (n=20) 组.
- 使用多维预后指数 (MPI) 评估的脆弱性.
- 血生物标志物的分析 (Aβ42,Aβ42/40,p-tau181,NfL) 和与CSF生物标志物的相关性.
主要成果:
- 阿尔茨海默症组的血p-tau181水平和MPI得分较高.
- MPI与血p-tau181正相关 (β=4.26,p=0.009).MPI与血p-tau181正相关 (β=4.26,p=0.009).MPI与血p-tau181正相关 (β=4.26,p=0.009).
- 血p-tau181与脑p-tau181和Aβ42/40有很强的相关性,实现了高的诊断准确性 (AUC = 0.910);结合MPI改善了分类 (AUC = 0.941).
结论:
- 使用MPI进行脆弱性评估,在阿尔茨海默病的诊断过程中非常有价值.
- 将老年评估与基于血液的生物标志物的整合可以提高早期AD检测.
- 这种综合方法促进了更全面的痴呆症评估策略.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806


